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IMPORTANCE Many patients with diabetic peripheral neuropathy experience chronic pain and
inadequate relief despite best available medical treatments.
OBJECTIVE To determine whether 10-kHz spinal cord stimulation (SCS) improves outcomes
for patients with refractory painful diabetic neuropathy (PDN).
DESIGN, SETTING, AND PARTICIPANTS The prospective, multicenter, open-label SENZA-PDN
randomized clinical trial compared conventional medical management (CMM) with 10-kHz
SCS plus CMM. Participants with PDN for 1 year or more refractory to gabapentinoids and at
least 1 other analgesic class, lower limb pain intensity of 5 cm or more on a 10-cm visual
analogue scale (VAS), body mass index (calculated as weight in kilograms divided by height in
meters squared) of 45 or less, hemoglobin A1c (HbA1c) of 10% or less, daily morphine
equivalents of 120 mg or less, and medically appropriate for the procedure were recruited
from clinic patient populations and digital advertising. Participants were enrolled from
multiple sites across the US, including academic centers and community pain clinics, between
August 2017 and August 2019 with 6-month follow-up and optional crossover at 6 months.
Screening 430 patients resulted in 214 who were excluded or declined participation and 216
who were randomized. At 6-month follow-up, 187 patients were evaluated.
INTERVENTIONS Implanted medical device delivering 10-kHz SCS.
MAIN OUTCOMES AND MEASURES The prespecified primary end point was percentage of
participants with 50% pain relief or more on VAS without worsening of baseline neurological
deficits at 3 months. Secondary end points were tested hierarchically, as prespecified in the
analysis plan. Measures included pain VAS, neurological examination, health-related quality of
life (EuroQol Five-Dimension questionnaire), and HbA1c over 6 months.
RESULTS Of 216 randomized patients, 136 (63.0%) were male, and the mean (SD) age was 60.8
(10.7) years. Additionally, the median (interquartile range) duration of diabetes and peripheral
neuropathy were 10.9 (6.3-16.4) years and 5.6 (3.0-10.1) years, respectively. The primary end
point assessed in the intention-to-treat population was met by 5 of 94 patients in the CMM
group (5%) and 75 of 95 patients in the 10-kHz SCS plus CMM group (79%; difference, 73.6%;
95% CI, 64.2-83.0; P < .001). Infections requiring device explant occurred in 2 patients in the
10-kHz SCS plus CMM group (2%). For the CMM group, the mean pain VAS score was 7.0 cm
(95% CI, 6.7-7.3) at baseline and 6.9 cm (95% CI, 6.5-7.3) at 6 months. For the 10-kHz SCS plus
CMM group, the mean pain VAS score was 7.6 cm (95% CI, 7.3-7.9) at baseline and 1.7 cm (95% CI,
1.3-2.1) at 6 months. Investigators observed neurological examination improvements for 3 of 92
patients in the CMM group (3%) and 52 of 84 in the 10-kHz SCS plus CMM group (62%) at 6
months (difference, 58.6%; 95% CI, 47.6-69.6; P < .001).
CONCLUSIONS AND RELEVANCE Substantial pain relief and improved health-related quality of
life sustained over 6 months demonstrates 10-kHz SCS can safely and effectively treat
patients with refractory PDN.
TRIAL REGISTRATION ClincalTrials.gov Identifier: NCT03228420
JAMA Neurol. doi:10.1001/jamaneurol.2021.0538
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T he World Health Organization estimates a total of 422million adults with diabetes worldwide and a world-wide prevalence (8.5%) that has nearly doubled over 4
decades.1 Diabetes may cause systemic damage with pro-
found impact on health-related quality of life and is poten-
tially life threatening. Diabetic peripheral neuropathy is a
common complication presenting as pain and other dysesthe-
sias, including numbness, burning, or tingling. Approxi-
mately 20% of patients with diabetes will develop painful dia-
betic neuropathy (PDN), a progressive, potentially debilitating
chronic neuropathic pain condition.2
Current PDN treatments include neuropathic pain medica-
tions, such as gabapentinoids, serotonin-norepinephrine
reuptake inhibitors, tricyclic antidepressants, opioids, and topi-
cal solutions.3,4 High-quality randomized clinical trials (RCTs)
demonstrate limited efficacy of these medications with high in-
cidence of adverse effects. Gabapentinoids may increase the risk
of respiratory depression, a serious concern for patients taking
opioids or with underlying respiratory impairment.5-7 System-
atic review and meta-analysis of neuropathic pain medication
RCTs reported a number needed to treat ranging from 3.6 to 7.7,
with a number needed to harm ranging from 11.8 to 25.6.8
Gabapentin and pregabalin are commonly prescribed for
PDN, but long-term adherence can be poor, with more than
60% of patients discontinuing by 6 months.9 Duloxetine re-
veals a similar pattern, with 50% discontinuing by 6 months.9
Most of these patients do not switch to an alternative therapy,
leaving their progressive neuropathic pain condition un-
treated. This represents a large patient population with sig-
nificant unmet needs.
Nonpharmacological PDN treatment with spinal cord
stimulation (SCS) devices was first reported in 1996.10,11 Two
prior RCTs demonstrated moderate utility of low-frequency
(40- to 60-Hz) SCS with smaller samples (36 to 60 partici-
pants) and 6-month to 24-month follow-up.12-14 Long-term fol-
low-up of low-frequency SCS shows responder attrition within
12 months.15 Observational data suggest high-frequency (10-
kHz) SCS provides substantial pain relief for patients with PDN
without generating paresthesias required for other types of
SCS.16-18 Previous results support 10-kHz SCS as a superior treat-
ment compared with low-frequency SCS for chronic low back
and leg pain and effective for nonsurgical low back pain, up-
per limb and axial neck pain, and neuropathic limb pain while
reducing opioid dosages.19-28
The Comparison of 10 kHz SCS Combined With CMM to
CMM Alone in the Treatment of Neuropathic Limb Pain
(SENZA-PDN) RCT29 extends observations from low-
frequency SCS studies in, to our knowledge, the largest RCT
to date to test the hypothesis that 10-kHz SCS combined with
conventional medical management (CMM) provides mean-
ingful pain relief compared with CMM alone for patients with
refractory PDN.
Methods
Detailed methods have been previously described.29 The West-
ern Institutional Review Board and local institutional review
boards approved the protocol, consent form, and study docu-
ments prior to study commencement at each site. Partici-
pants were enrolled after providing written informed
consent. The study was conducted in accordance with the Dec-
laration of Helsinki30 as well as good clinical practices and re-
ported in accordance with the Consolidated Standards of Re-
porting Trials (CONSORT) reporting guideline. Participants
reported demographic information, including race/ethnicity,
and those data were summarized. The study protocol can be
found in Supplement 1, and the statistical analysis plan can be
found in Supplement 2. The study design has been previously
published.29
Design and Outcomes
Patients with PDN were recruited across multiple sites in the
US. Key inclusion criteria were PDN diagnosis with symp-
toms for 12 months or more that was refractory to treatment
with gabapentin or pregabalin and at least 1 other class of an-
algesic, lower limb pain intensity of 5 cm or more on a 10-cm
visual analogue scale (VAS), and medically suitable for the pro-
posed procedure. All patients were psychologically evalu-
ated and reviewed by independent medical monitors prior to
randomization. Key exclusion criteria were hemoglobin A1c
(HbA1c) greater than 10%, body mass index (calculated as
weight in kilograms divided by height in meters squared)
greater than 45, daily opioid dosage greater than 120 mg mor-
phine equivalents, and upper limb pain intensity of 3 cm or
more on a VAS. The primary measure for pain was the VAS.31
Additional pain qualities were assessed by Short-Form McGill
Pain Questionnaire (SF-MPQ-2), Douleur Neuropathique
(DN4), and modified Neuropathy Symptom Score.32-34 Health-
related quality of life measures included the Pain and Sleep
Questionnaire, Global Assessment of Functioning, EuroQol
5-Dimension Questionnaire (EQ-5D-5L), and patient
satisfaction.35,36 Patient safety was assessed via adverse event
(AE) monitoring and thorough neurological assessment. A clini-
cal events committee provided oversight of AEs.
Two independent neurologists designed the standard-
ized neurological examination and trained investigators. Lower
limb motor function, light touch sensation, and reflexes were
assessed in standard fashion developed in collaboration with
the US Food and Drug Administration for a prior study.19,20 The
neurological assessment also included a 10-point diabetic foot
Key Points
Question Will 10-kHz spinal cord stimulation improve pain relief
for patients with painful diabetic neuropathy refractory to medical
management?
Findings In this randomized clinical trial including 216 patients,
there was a significant benefit of 10-kHz spinal cord stimulation,
with 79% of treatment responders whose underlying neurological
deficits did not worsen compared with 5% of controls treated with
conventional medical management.
Meaning Patients with painful diabetic neuropathy with
inadequate pain relief despite best available medical treatments
should be considered for 10-kHz spinal cord stimulation.
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examination with pinprick and Semmes-Weinstein 10-g mono-
filament testing (eFigure 1 in Supplement 3). Neuropen (Owen
Mumford Ltd) was used to deliver consistent, reproducible
pressure for testing these modalities, as this has been shown
most accurate among commercially available products.37 The
neurological assessment was conducted at baseline and fol-
low-up visits and is consistent with American Diabetes Asso-
ciation recommendations for assessing loss of protective sen-
sation as well as American Academy of Neurology’s definition
of distal symmetric polyneuropathy.38,39 Investigators used
clinical judgment to determine if observed changes were clini-
cally meaningful.
Randomization and Follow-up
Treatment allocations were concealed with computer assign-
ment 1:1 to CMM or 10-kHz SCS plus CMM. Randomization was
performed using a random-sized block method by site and
stratified by pain severity (VAS) and glycemic control (HbA1c).
Data collection will continue for 24 months. Patients could opt
to cross over to the other treatment arm at 6 months if they
had insufficient pain relief (less than 50% improvement), were
dissatisfied with treatment, and were appropriate to proceed
as determined by their physician.
SCS Treatment
Patients assigned to the SCS treatment group underwent
temporary trial stimulation for 5 to 7 days with percutaneous
leads placed epidurally along T8 to T11 (eFigure 2 in Supple-
ment 3). Patients reporting 50% or more pain relief using the
VAS were eligible for permanent SCS device implant (Nevro
Corp), which included 2 percutaneous leads placed epidur-
ally connected to an implantable pulse generator typically
placed in the low back. Stimulation parameters included
10-kHz frequency, 30-μs pulse width delivered via bipole,
and amplitude range of 0.5 to 3.5 mA. Optimal bipole loca-
tion and amplitude were adjusted per patient feedback, as
previously described.19
Statistical Analysis
Baseline characteristics were compared for potential imbal-
ance by a standardized difference effect size index (Cohen d).
Primary end point outcome was a composite of effectiveness
and stable neurological examination requiring 50% or more
pain relief by VAS without a meaningful worsening of base-
line neurological deficits at 3-month follow-up. Primary
analysis involved the intention-to-treat population with
known status, with a secondary analysis in the per-protocol
population of patients who completed 3-month follow-up as
assigned, assessed by Fisher exact test with 2-sided α level of
.05. The effects of missing outcome data on the primary end
point comparison between groups were examined in sensi-
tivity analyses (eTable 1 in Supplement 3). Beyond primary
end point analysis of the intention-to-treat population, out-
comes are reported for the per-protocol population as means
with 95% CIs. A hierarchical closed testing procedure was
performed to control type I error in evaluating significant dif-
ferences in secondary end points. If the primary end point
was met, there were 8 prespecified secondary end points that
were tested successively with Fisher exact test or t test, as
appropriate, until significance could not be demonstrated at
a 2-sided α level of .05.29 Results through 6 months are
reported, including the primary end point at 3 months and all
secondary end points: 2 assessed at 3 months and 6 assessed
at 6 months. We conducted analyses using SPSS Statistics
version 25 (IBM).
Results
Patients were enrolled at 18 research sites across the US, in-
cluding academic centers and independent pain clinics, be-
tween August 28, 2017, and August 23, 2019. Screening 430
candidates resulted in 216 patients with PDN who were ran-
domized (Figure 1). Of these 216 randomized patients, 136
(63.0%) were male, and the mean (SD) age was 60.8 (10.7) years.
Screening failures included ineligibility per inclusion or
exclusion criteria (n = 146) and patient decision (n = 65). Ran-
domized patients included 103 assigned to CMM and 113 as-
signed to 10-kHz SCS plus CMM.
Among 216 randomized patients, the mean (SD) HbA1c was
7.4% (1.2) and mean (SD) body mass index was 33.7 (5.3). A total
of 130 patients (60.2%) had suboptimally controlled diabe-
tes. The median (interquartile range) duration of diabetes and
peripheral neuropathy were 10.9 (6.3-16.4) years and 5.6 (3.0-
10.1) years, respectively, before enrollment. There was a simi-
lar distribution of sex between groups (Table). Patients pre-
sented with moderate to severe neuropathic pain indicated by
a mean (SD) baseline VAS score of 7.3 (1.6) cm and a mean (SD)
DN4 score of 6.6 (1.8).
Primary End Point Assessment
In the CMM group, 5 of 94 patients (5%) met the composite
primary end point of 50% or more pain relief using the VAS
without observed deterioration on neurological examination
compared with 75 of 95 in the 10-kHz SCS plus CMM group
(79%; difference, 73.6%; 95% CI, 64.2-83.0; P < .001). Sensi-
tivity analyses considered varying assumptions for missing
data with no effect on the conclusion that the treatment
effect for 10-kHz SCS plus CMM was superior to CMM alone
(eTable 1 in Supplement 3). The intention-to-treat population
with known status included temporary trial stimulation fail-
ures (n = 6) and patients who exited the study due to an AE
(n = 2) as nonresponders in the 10-kHz SCS plus CMM group.
One patient in the 10-kHz SCS plus CMM group and 2 in the
CMM group missed 3-month follow-up but continued in the
study. These patients were considered part of the safety
population but excluded from the defined per-protocol
population, with data reported separately (eTable 2 in
Supplement 3).
Safety
There were no study-related AEs reported for the CMM group
as the protocol did not require any specific treatments, while
there were 18 AEs reported among 14 patients in the 10-kHz
SCS plus CMM group (eTable 3 in Supplement 3). There were
3 study-related AEs for infection, 2 for wound dehiscence, and
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1 for impaired healing among 5 of 90 patients (6%). Of 90 total
implanted patients, 2 (2%) required explant. There were no
stimulation-related neurological deficits in the 10-kHz SCS plus
CMM group. A clinical events committee reviewed all AEs pe-
riodically with no concerns about the conduct of the study.
Secondary End Point Assessments
A summary table of all secondary end point outcomes is shown
in order of hierarchical analysis in eTable 4 in Supplement 3.
Pain Relief During Trial SCS
In the 10-kHz SCS plus CMM treatment arm, 104 patients com-
pleted a temporary trial with SCS, with 98 achieving 50% or
more pain relief using the VAS (94% success) and eligible for
implantation of a permanent system (Figure 1). The mean pain
VAS score at the end of the trial was 1.3 cm (95% CI, 1.0-1.6), a
mean 82.3% (95% CI, 78.5-86.1) reduction from baseline.
The 6 patients who failed temporary trial SCS continued
with CMM (eTable 5 in Supplement 3). A total of 90 patients
in the 10-kHz SCS plus CMM group received permanent
device implants.
Pain Relief at 3 and 6 Months
At 3-month follow-up, 5 of 96 in the CMM group (5%) had pain
VAS scores of 3 cm or less compared with 69 of 88 in the 10-
kHz SCS plus CMM group (78%; difference, 73.2%; 95% CI, 63.5-
82.9; P < .001) (Figure 2A). At 6-month follow-up, there was
no change in mean pain VAS scores for the CMM group, with a
baseline mean of 7.0 cm (95% CI, 6.7-7.3) and a 6-month mean
of 6.9 cm (95% CI, 6.5-7.3); however, lower limb pain VAS scores
Figure 1. Disposition of All Patients Screened for Study Participation
430 Assessed for eligibility
214 Excluded
146 Did not meet inclusion or exclusion criteria
65 Declined to participate
3 Not randomized because enrollment ended
216 Randomized
2 Excluded
1 Lost to follow-up
1 Left due to adverse events
103 Randomized to conventional
medical management
113 Randomized to 10-kHz spinal cord stimulation
plus conventional medical management
90 Included in the 1-mo analysis
11 Missed the visit
4 Included in the 1-mo analysis
1 Missed the visit
1 Withdrew consent
90 Included in the 1-mo analysis
88 Included in the 3-mo analysis
1 Missed the visita
1 Left due to adverse events
96 Included in the 3-mo analysis
1 Left due to adverse events
2 Missed the visita
2 Lost to follow-up
4 Included in the 3-mo analysis
1 Lost to follow-up
104 Included in trial SCS
90 Implanted
87 Included in the 6-mo analysis
1 Included in the safety groupa
1 Left due to adverse events
4 Included in the 6-mo analysis93 Included in the 6-mo analysis
2 Included in the safety groupa
2 Withdrew consent
1 Lost to follow-up
6 Trial SCS failures
9 Excluded
5 Withdrew consent
1 Lost to follow-up
3 Left due to adverse events
8 Excluded
4 Declined implantable pulse
generators
1 Left due to adverse events
3 Lost to follow-up
a Patients who missed the 3-month primary end point assessment (2 patients in
the conventional medical management group, 1 in the 10-kHz spinal cord
stimulation plus conventional medical management group) were considered
part of the safety population but excluded from the per-protocol population
for other outcome assessments even though they completed the 6-month
visit.
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differenceaCMM (n = 103)
10-kHz SCS plus CMM
(n = 113)
Age, y
Mean (SD) 60.8 (9.9) 60.7 (11.4)
0.01
Median (IQR) 62.0 (55.0-67.5) 61.0 (55.0-70.0)
Sex
Male 66 (64.1) 70 (61.9)
0.04
Female 37 (35.9) 43 (38.1)
Race
White 85 (82.5) 87 (77.0)
0.14
Black or African American 13 (12.6) 18 (15.9)
Native Hawaiian or other Pacific Islander 1 (1.0) 3 (2.7)
American Indian or Alaska Native 0 2 (1.8)
Asian 1 (1.0) 1 (0.9)
Other 3 (2.9) 2 (1.8)
Diabetes
Type 1 3 (2.9) 8 (7.1)
0.19
Type 2 100 (97.1) 105 (92.9)
Duration, y
Diabetes
Mean (SD) 12.2 (8.5) 12.9 (8.5)
0.09
Median (IQR) 10.4 (6.3-15.2) 12.0 (6.4-18.6)
Peripheral neuropathy
Mean (SD) 7.1 (5.1) 7.4 (5.7)
0.06
Median (IQR) 5.4 (2.9-10.0) 5.7 (3.1-10.1)
Lower limb pain VAS
Mean (SD), cm 7.1 (1.6) 7.5 (1.6)
0.22
Median (IQR), cm 7.2 (6.2-8.2) 7.5 (6.6-8.6)
<7.5 cm 57 (55.3) 54 (47.8)
0.15
≥7.5 cm 46 (44.7) 59 (52.2)
HbA1c
Mean (SD), % 7.4 (1.2) 7.3 (1.1)
0.11
Median (IQR), % 7.3 (6.6-8.2) 7.3 (6.3-8.2)
<7.0% 40 (38.8) 46 (40.7)
0.04
≥7.0% 63 (61.2) 67 (59.3)
BMIb
Mean (SD) 33.9 (5.2) 33.6 (5.4)
0.06
Median (IQR) 34.3 (30.9-37.1) 33.6 (29.8-36.3)
Severity of neuropathic pain
DN4
Mean (SD) 6.5 (1.9) 6.6 (1.7)
0.12
Median (IQR) 6 (5-8) 7 (5-8)
<3 3 (2.9) 1 (0.9)
0.15
≥3 99 (97.1) 112 (99.1)
mNSS
Mean (SD) 6.9 (1.1) 6.8 (1.3)
0.05
Median (IQR) 7 (6-8) 7 (6-8)
Mild (3-4) 2 (2.0) 2 (1.8)
NAModerate (5-6) 33 (32.4) 46 (40.7)
Severe (7-9) 67 (65.7) 65 (57.5)
(continued)
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decreased by a mean of 76.3% (95% CI, 70.8-81.8) for the im-
planted group. Patients in the 10-kHz SCS plus CMM group had
a mean baseline pain VAS score of 7.6 cm (95% CI, 7.3-7.9) and
a 6-month mean pain VAS score of 1.7 cm (95% CI, 1.3-2.1)
(Figure 2B). Individual responses revealed worsening pain for
48 of 93 patients in the CMM group (52%) and 2 of 87 in the
10-kHz SCS plus CMM group (2%) (Figure 2C). The proportion
of responders, defined as 50% or more pain relief from base-
line VAS, was 5% (5 of 93) in the CMM group compared with
85% (74 of 87) in the 10-kHz SCS plus CMM group at 6 months
(P < .001) (Figure 2C). In addition, 53 of 88 patients in the 10-
kHz SCS plus CMM group (60%) achieved remission of pain,
defined as VAS score of 3 cm or less sustained for 6 months,40
compared with 1 of 95 in the CMM group (1%; P < .001).
Neurological Assessment at 3 and 6 Months
Investigators assessed meaningful worsening or improve-
ment in motor, sensory, or reflex testing. Improvement from
baseline without any worsening on examination was noted in
6 patients in the CMM group (6%) and 63 in the 10-kHz SCS
plus CMM group (72%) at 3 months (difference, 66.0%; 95%
CI, 55.4-76.6; P < .001) and 3 patients in the CMM group (3%)
and 52 in the 10-kHz SCS plus CMM group (62%) at 6 months
(difference, 58.6%; 95% CI, 47.6-69.6; P < .001) (Figure 3A).
Most of the improvements were in sensory assessment. A total
of 17 patients in the CMM group (19%) and 5 in the 10-kHz SCS
plus CMM group (6.0%) demonstrated a meaningful deficit at
6 months compared with baseline.
A DN4 score of 3 or more is consistent with clinically con-
firmed PDN.41 The mean DN4 score for patients in the CMM
group was 6.4 (95% CI, 6.2-6.6) at baseline and 6.5 (95% CI,
6.3-6.7) at 6 months. A total of 88 of 91 patients in the CMM
group had a DN4 baseline score of 3 or more. This decreased
by 1.1% to 87 of 91 patients at 6 months (Figure 3B). For those
in the 10-kHz SCS plus CMM group, the mean score was 6.5
(95% CI, 6.3-6.7) at baseline and 3.5 (95% CI, 3.2-3.8) at 6
months. A total of 83 of 84 patients in this group had a base-
line score of 3 or more. This decreased by 34.5% to 54 of 84
patients at 6 months.
Treatment groups were well matched for intensity in all 4
SF-MPQ-2 subscales at baseline: continuous pain, intermit-
tent pain, neuropathic pain, and affective descriptors
(Figure 3C). There was no change for those in the CMM group
over 6-month follow-up, whereas all subscales improved for
those in the 10-kHz SCS plus CMM group, including a mean
67.0% (95% CI, 58.6-75.4) improvement in the intensity of af-
fective descriptors.
Health-Related Quality of Life at 6 Months
Each group rated overall health equivalently at baseline on
EQ-5D-5L VAS (Figure 4A). There was no change for those in
the CMM group but a mean 16-point (95% CI, 11.3-20.5) im-
provement for those in the 10-kHz SCS plus CMM group
(P < .001). The mean EQ-5D-5L index score was 0.630 (95%
CI, 0.600-0.660) for those in the CMM group at baseline and
decreased to 0.599 (95% CI, 0.566-0.632) at 6 months
(Figure 4A). For those in the 10-kHz SCS plus CMM group, the
mean EQ-5D-5L index score of 0.636 (95% CI, 0.604-0.668)
at baseline improved to 0.765 (95% CI, 0.737-0.793; P < .001)
at 6 months, a difference of 0.129. The minimally important
difference is estimated between 0.03 to 0.05 in the type 2 dia-
betes population.42
The effect of pain on sleep quality was evident in both arms
at baseline (Figure 4B). In the CMM group, sleep disturbance
due to pain increased by 5.3% (95% CI, −15.0 to 4.4), while in
the 10-kHz SCS plus CMM group, there was a mean 61.9% (95%
Abbreviations: BMI, body mass index; CMM, conventional medical
management; DN4, Douleur Neuropathique;
HbA1c, hemoglobin A1c; IQR, interquartile range; mNSS, modified Neuropathy
Symptom Score; NA, not applicable;
SCS, spinal cord stimulation; SNRI, serotonin-norepinephrine reuptake inhibitor;
TCA, tricyclic antidepressant;
VAS, visual analogue scale.
a Possible imbalances in baseline characteristics were evaluated with a
standardized difference effect size index (Cohen d). Index scores less than
0.20 suggest the groups are well matched, whereas scores of 0.20 or greater
indicate small differences, of 0.50 or greater indicate medium differences, and
of 0.80 or greater indicate large differences between the groups.
b Calculated as weight in kilograms divided by height in meters squared.




differenceaCMM (n = 103)




Gabapentin 50 (48.5) 63 (55.8) 0.14
Pregabalin 29 (28.2) 25 (22.1) 0.14
Antidepressants
SNRIs 29 (28.2) 25 (22.1) 0.14
TCAs 14 (13.6) 10 (8.8) 0.15
Opioids 44 (42.7) 50 (44.2) 0.03
Topicals 9 (8.7) 11 (9.7) 0.03
Diabetes medications
Insulin 47 (45.6) 51 (45.1) 0.01
Oral and noninsulin injectable medications 84 (81.6) 88 (77.9) 0.09
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CI, 54.4-69.4) reduction. Investigators evaluated patients’
well-being with the Global Assessment of Functioning
(Figure 4C). No change was observed for those in the CMM
group, while patients in the 10-kHz SCS plus CMM group
had a mean improvement of 17.7 points (95% CI, 13.8-21.6).
At 6-month follow-up, 80 of 87 in the 10-kHz SCS plus CMM
group (92%) reported being satisfied or very satisfied with
their treatment compared with 6 of 93 in the CMM group
(6%) (Figure 4D).
For patients in the CMM group, the mean HbA1c level was
7.4% (95% CI, 7.1-7.6) at baseline, with a mean increase of 2.6%
(95% CI, −0.7 to 5.8) over 6 months. In the 10-kHz SCS plus
CMM group, the mean HbA1c was 7.4% (95% CI, 7.1-7.6) at base-
line, with a mean increase of 1.5% (95% CI, −1.8 to 4.7) over 6
months. There was no difference between the groups in the
mean change over 6 months (P = .65).
Patients could opt to cross over to the other treatment
arm at 6 months if they met all 3 prespecified criteria: less
than 50% pain relief using the VAS from baseline, dissatis-
faction with the current treatment, and investigator agree-
ment the patient was medically appropriate to proceed.
None of the patients in the 10-kHz SCS plus CMM group met
the criteria for crossover, whereas 76 of 93 in the CMM
group (82%) both met criteria and elected to cross over
(P < .001).
Discussion
This study—the largest RCT for SCS treatment of PDN to
date—was designed as a pragmatic study to provide high-
level evidence in guiding clinical decision-making. Partici-
pants had long-standing diabetes and well-established PDN.
Inclusion and exclusion criteria were consistent with the
greater population of patients with refractory PDN. Previous
treatments, including medications, followed best-practice
guidelines.3,4
The proportion of treatment responders to high-frequency
(10-kHz) SCS at 6 months (85%) surpasses that of 2 published
RCTs comparing low-frequency SCS with CMM.12-14 de Vos et al12
reported a 69% responder rate at 6 months among 36 indi-
viduals with PDN. Slangen and colleagues14 reported a 56%
responder rate at 6 months among 16 individuals with PDN.
Long-term follow-up of 22 patients with PDN reveals 36%
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Mean lower limb pain VAS scores over timeB
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10-kHz SCS plus CMM
Change from baseline pain VAS, %
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A, Proportion of patients with at least 50% pain relief on a VAS from baseline or
lower limb pain of 3 cm or less using the VAS at 1, 3, and 6 months for
conventional medical management (CMM) and 10-kHz spinal cord stimulation
(SCS) plus CMM. B, Mean lower limb pain scores on the VAS over time for 93
patients in the CMM group and 87 patients in the 10-kHz SCS plus CMM group.
Error bars indicate 95% CIs. C, Individual pain response. Each line represents
the change in a single patient’s lower limb pain VAS score at 6 months relative
to baseline for 93 patients in the CMM group and 87 in the 10-kHz SCS plus
CMM group. The dotted blue line represents the threshold for treatment
responders of at least 50% pain relief. In the CMM group, 5% of patients were
responders compared with 85% of patients in the 10-kHz SCS plus CMM group
(orange boxes).
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responders to low-frequency SCS at 5 years with severity of
neuropathy predictive of treatment failure.15 Improvements
in neurological function were not reported in prior low-
frequency SCS studies. Additionally, 10-kHz SCS provides pain
relief without exacerbating underlying paresthesias as it is the
only paresthesia-independent SCS device.18 This study pro-
vides level I evidence supporting the addition of 10-kHz SCS
to CMM for patients with PDN with symptoms refractory to
medical management.
There are several RCTs evaluating pharmacological PDN
treatments demonstrating lower responder rates than SCS.
Meta-analysis of pregabalin data with 4-week to 12-week
follow-up yielded a responder rate of 47% for 600 mg
daily.43 Studies for duloxetine with 8-week to 12-week
follow-up reported 42% to 59% responders.44 Tapentadol
therapy resulted in 40% responders at 15 weeks.45 Longer-
term data are lacking for PDN pharmacotherapy.
Effectiveness of 10-kHz SCS PDN treatment exceeds
results reported for other pain etiologies. A large RCT dem-
onstrated responder rates of 76% for back pain and 81% for
leg pain at 6 months.19 A prospective, multicenter, observa-
tional study reported 78% responders for axial neck pain
and 88% for upper limb pain at 6 months.23 Nonsurgical
patients with refractory back pain treated with 10-kHz SCS
resulted in 75% responders at 6 months and 80% at 36
months.22,46 Two prior studies have described long-term
benefit of 10-kHz SCS for peripheral polyneuropathy.16,17
The current study extends these initial observations with
level I evidence.
Wound complications are a primary concern when per-
forming surgical procedures for patients with diabetes.
Combined incidence of wound dehiscence, impaired heal-
ing, or infection was seen in 5 of 90 patients with perma-
nent SCS implant, a 5.6% wound complication rate. This is
consistent with the risk for SCS wound complications in
general and suggests implantation of an SCS device can be
safely accomplished in patients with diabetes.47
Improvements in sensation, as observed by investigators in
mostpatientsreceiving10-kHzSCSplusCMM,isunreportedwith
other SCS therapies and supports similar findings in observa-
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<3
≥3
CMM 10-kHz SCS plus CMM
A, Proportion of patients with clinically meaningful improvement in motor,
sensory, or reflex neurological examination scores and without a clinically
meaningful deficit in any category as determined by the investigator at 6
months compared with baseline for 92 patients in the conventional medical
management (CMM) group and 84 in the 10-kHz spinal cord stimulation (SCS)
plus CMM group. B, Distribution of patients over time with Douleur
Neuropathique (DN4) score of less than 3 and 3 or more for 91 patients in the
CMM group and 84 in the 10-kHz SCS plus CMM group. DN4 score measures
the severity of neuropathic pain. C, Mean Short-Form McGill Pain Questionnaire
(SF-MPQ-2) scores for each subscale at baseline and 6 months for 93 patients in
the CMM group and 87 in the 10-kHz SCS plus CMM group. SF-MPQ-2 is a
patient-reported measure of the intensity of pain descriptors. Error bars
indicate 95% CIs.
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tional studies of this treatment in those with peripheral poly-
neuropathy of various etiologies.16,17 Existing pharmacological
treatments for PDN may mitigate pain symptoms without ef-
fect on underlying pathophysiology.3,48 Interestingly, changes
in sensation were observed often by the end of trial stimulation
and persisted over the course of follow-up. Further studies are
needed to elucidate potential mechanisms of action but may
involve increased blood flow to the periphery, improvement
in peripheral or central sensory processing, and/or changes in
intraepidermal nerve fiber density.49,50 Improved sensation
has potential advantages for patients with diabetic peripheral
neuropathy that could aid in foot ulcer or infection reduction
and possibly enhance proprioception that would reduce risk
of falling and potential injury. This study applied standard
clinical assessments of neurological function; however, asses-
sor variability can be significant, and the findings of neuro-
logical improvements should be interpreted in the context of
this limitation. Further study including more objective mea-
sures will be required to validate these observations.
Chronic pain, regardless of etiology, negatively affects sleep
quality. This can be especially true for patients with PDN with
symptoms classically worse at night. Prior RCT data with
low-frequency SCS reported half the participants achieved
significant pain relief at night.14 Sleep deprivation exacer-
bates underlying disease, affects mental health, and daytime
functioning. This study indicates that 10-kHz SCS greatly im-
proves sleep for patients with PDN. In addition, patients im-
proved across a variety of health-related quality of life mea-
sures, suggesting a broad effect of this treatment on patients’
lives.
Limitations
This study had limitations. Comparing an implanted medi-
cal device with best available medical treatment made
blinding impossible. Steps were taken to mitigate bias,
including random sequence generation and concealed treat-
ment allocation. The cohorts were well matched at baseline,
attrition was acceptable, missing data were unlikely to have
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Overall health VAS score
10-kHz SCS plus CMMCMM
A, Mean EuroQol 5-Dimension Questionnaire (EQ-5D-5L) overall health visual
analogue scale (VAS) score (left) and index score (right) for 92 patients in the
conventional medical management (CMM) group and 87 in the 10-kHz spinal
cord stimulation (SCS) plus CMM group from baseline to 6 months. The
minimally important difference in index scores is estimated between 0.03 to
0.05. B, Mean scores for the Pain and Sleep Questionnaire assessing how often
pain disturbs sleep. A score of 0 indicates never and a score of 10 indicates
always. Scores are shown for 93 patients in the CMM group and 87 in the
10-kHz SCS plus CMM group. C, Mean scores on Global Assessment of
Functioning at baseline and at 1, 3, and 6 months for 91 patients in the CMM
group and 86 in the 10-kHz SCS plus CMM group. The Global Assessment of
Functioning represents the physician’s evaluation of how much a patient’s
symptoms affect psychological, social, and occupational functioning. D, Patient
satisfaction with treatment at 6 months. Scores are shown for 93 patients in the
CMM group and 87 in the 10-kHz SCS plus CMM group. Error bars indicate
95% CIs.
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a meaningful effect on the outcomes, and all primary and
secondary outcomes have been reported as prespecified.
Nonetheless, lack of blinding may influence patients and
investigators. Potential placebo effects in this study may be
significant with an active device treatment. Long-term
follow-up may mitigate concerns about a placebo effect.
This study included patients with symptoms refractory
to evidence-based CMM at baseline—10-kHz SCS was added
in the treatment arm to explore if satisfactory benefit could
be achieved. The control arm reflects a sizable patient popu-
lation for whom currently available treatments provide
insufficient pain relief; however, generalizing to all patients
with PDN warrants caution. The findings of neurological
improvements should be interpreted in the context of these
limitations.
Conclusions
Patients with PDN refractory to best available treatments
can be safely and effectively treated with high-frequency
(10-kHz) SCS. Evidence-based treatment guidelines should
contemplate positioning of 10-kHz SCS in the continuum of
care. Follow-up of this study population will continue for 24
months and establish potential durability of this treatment
beyond 6 months. Patients experienced substantial, sus-
tained pain relief as well as clinically assessed improve-
ments in neurological function and improved health-related
quality of life. In practice, patients with PDN with inad-
equate response to conventional treatments should be con-
sidered for 10-kHz SCS.
ARTICLE INFORMATION
Accepted for Publication: January 27, 2021.
Published Online: April 5, 2021.
doi:10.1001/jamaneurol.2021.0538
Open Access: This is an open access article
distributed under the terms of the CC-BY-NC-ND
License. © 2021 Petersen EA et al. JAMA Neurology.
Author Affiliations: Department of Neurosurgery,
University of Arkansas for Medical Sciences,
Little Rock (Petersen); Advanced Pain
Management, Greenfield, Wisconsin (Stauss,
Tsoulfas); Pain Management Associates, Lee’s
Summit, Missouri (Scowcroft, Israel); Nevro Corp,
Redwood City, California (Brooks, Caraway); AES
Compass Orlando, Orlando, Florida (White);
Touchstone Interventional Pain Center, Medford,
Oregon (Sills); IPM Medical Group, Walnut Creek,
California (Amirdelfan); Ochsner Health System,
New Orleans, Louisiana (Guirguis, Harrison);
Department of Pain Management, Cleveland Clinic
Foundation, Cleveland, Ohio (Xu, Mekhail); Swedish
Medical Center, Seattle, Washington (Yu); Nevada
Advanced Pain Specialists, Reno, Nevada (Nairizi,
Patterson); Central Florida Pain Relief Centers,
Orlando, Florida (Creamer); Pain Care, Stockbridge,
Georgia (Galan, Chang); Coastal Orthopedics and
Sports Medicine, Bradenton, Florida (Bundschu,
Gekht); Department of Anesthesiology, University
of Arkansas for Medical Sciences, Little Rock (Paul,
Choi, Goree); Department of Anesthesiology, Weill
Cornell Medical College, New York, New York
(Mehta); Department of Anesthesiology and Pain
Medicine, University of Kansas Medical Center,
Kansas City (Sayed); Department of Neurosurgery,
Duke University, Durham, North Carolina (Lad);
Boston PainCare, Waltham, Massachusetts
(DiBenedetto); Department of Neurosurgery,
United Health Services, Johnson City, New York
(Sethi, Bennett); Holy Cross Hospital, Fort
Lauderdale, Florida (Wu); Department of
Neurology, Albany Medical Center, Albany,
New York (Argoff); Department of Endocrinology,
Cleveland Clinic Foundation, Cleveland, Ohio
(Nasr); MRC/CSO Social and Public Health Sciences
Unit, Robertson Centre for Biostatistics, Institute of
Health and Well Being, University of Glasgow,
Glasgow, Scotland, United Kingdom (Taylor); GTX
Medical Inc, Lexington, Massachusetts
(Subbaroyan); Independent Medical Device
Consultant, Seattle, Washington (Gliner).
Author Contributions: Dr Petersen had full access
to all of the data in the study and takes
responsibility for the integrity of the data and the
accuracy of the data analysis.
Study concept and design: Brooks, Sills, Amirdelfan,
Guirguis, Bundschu, Mehta, Sayed, Sethi, Argoff,
Taylor, Subbaroyan, Gliner, Caraway, Mekhail.
Acquisition, analysis, or interpretation of data:
Petersen, Stauss, Scowcroft, Brooks, White, Sills,
Guirguis, Xu, Yu, Nairizi, Patterson, Tsoulfas,
Creamer, Galan, Paul, Mehta, Choi, Sayed, Lad,
DiBenedetto, Goree, Bennett, Harrison, Israel,
Chang, Wu, Gekht, Argoff, Nasr, Taylor, Subbaroyan,
Gliner, Caraway.
Drafting of the manuscript: Petersen, Brooks, Sills,
Amirdelfan, Guirguis, Nairizi, Creamer, Sayed,
Argoff, Taylor, Caraway.
Critical revision of the manuscript for important
intellectual content: Petersen, Stauss, Scowcroft,
Brooks, White, Sills, Xu, Yu, Patterson, Tsoulfas,
Galan, Bundschu, Paul, Mehta, Choi, Sayed, Lad,
DiBenedetto, Sethi, Goree, Bennett, Harrison,
Israel, Chang, Wu, Gekht, Argoff, Nasr, Subbaroyan,
Gliner, Caraway, Mekhail.
Statistical analysis: Sills, Chang.
Obtained funding: Amirdelfan, Gliner, Caraway.
Administrative, technical, or material support:
Stauss, Brooks, Sills, Xu, Yu, Patterson, Tsoulfas,
Creamer, Bundschu, Paul, Choi, Sayed, Harrison,
Israel, Wu, Gekht, Subbaroyan, Gliner, Caraway.
Study supervision: Petersen, Stauss, Sills,
Amirdelfan, Yu, Nairizi, Galan, Bundschu, Mehta,
Choi, Sayed, Lad, DiBenedetto, Sethi, Wu, Argoff,
Taylor, Subbaroyan, Gliner, Caraway, Mekhail.
Conflict of Interest Disclosures: Drs Petersen,
Scowcroft, White, Sills, Amirdelfan, Guirguis, Xu,
Yu, Nairizi, Patterson, Galan, Mehta, Choi, Sayed,
Lad, DiBenedetto, Goree, Wu, Argoff, Nasr, Taylor,
and Mekhail have received personal fees from
Nevro Corp. Dr Petersen has received research
support from Medtronic, Neuros Medical, Nevro
Corp, and ReNeuron as well as personal fees from
Abbott Neuromodulation, Medtronic
Neuromodulation, and Neuros Medical.
Dr Scowcroft has received research support from
Boston Scientific, Nevro Corp, Saluda Medical, and
Vertiflex. Drs Brooks and Caraway are employees of
Nevro Corp. Dr White has received consulting fees
from Eli Lilly and Company and California Institute
for Biomedical Research. Dr Amirdelfan has
received research support from IPM Medical Group,
Biotronik, Vivex Biologics, Saluda Medical, and SPR
Therapeutics as well as personal fees from Nalu
Medical, Saluda Medical, Biotronik, and Medtronic.
Dr Guirguis has received personal fees from Avanos
Medical and SPR Therapeutics as well as research
support from Abbott Laboratories, Boston
Scientific, Neuros Medical, and Avanos Medical.
Dr Xu has received research support from the
Cleveland Clinic MENTR Program and the National
Institutes of Health. Dr Nairizi has received personal
fees from Flowonix. Dr Patterson has received
personal fees from Abbott Laboratories, AIS
Healthcare, Allergan, Amgen, CornerLoc, Nuvectra
Medical, and Saluda Medical as well as research
support from Abbott Laboratories, Biotronik,
Flowonix, Nuvectra Medical, and Vertiflex. Dr Galan
has received research support from Medtronic, SPR
Therapeutics, St Jude, Biotronik, and PainTEQ.
Dr Mehta has received personal fees from Salix
Pharmaceuticals, BioDelivery Sciences
International, and Sollis Therapeutics as well as
research support from Boston Scientific and
Medtronic. Dr Sayed has received personal fees
from Abbott Laboratories, Medtronic, Boston
Scientific, Flowonix, Vertos Medical, and Vertiflex;
research support from Abbott Laboratories,
Biotronic, Vertos Medical, and Vertiflex; and owns
equity in SPR Therapeutics. Dr DiBenedetto has
received funding for serving as principal
investigator of a study supported by SPR
Therapeutics paid to his institution. Dr Goree has
received personal fees from Abbott Laboratories
and Stratus Medical. Dr Argoff has received
research support from Allergan, Amgen, Daiichi
Sankyo, Novartis, Teva Pharmaceutical, Eli Lilly and
Company, and Vertex Pharmaceuticals as well as
personal fees from AbbVie, Teva Pharmaceutical,
Eli Lilly and Company, Novartis, Pfizer, Flowonix,
Vertex Pharmaceuticals, Elsevier, and SK Life
Science. Dr Nasr has received personal fees from
Neurogastrx and Exelixis. Dr Taylor has received
personal fees from Medtronic and Saluda Medical.
Dr Subbaroyan and Mr Gliner were employees of
Nevro Corp at the time this work was completed.
Dr Subbaroyan has a patent for painful diabetic
neuropathy and sensory modulation pending to
Nevro Corp and owns stocks in Nevro Corp.
Mr Gliner has a patent for HF10 therapy and related
issued to Nevro Corp. Dr Mekhail has received
personal fees from Boston Scientific, Sollis
Therapeutics, Saluda Medical, Abbott Laboratories
(formerly Spinal Modulation), Vertos Medical,
Nuvectra Medical, and Relievant Medsystems;
Research Original Investigation Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy
E10 JAMA Neurology Published online April 5, 2021 (Reprinted) jamaneurology.com
Downloaded From: https://jamanetwork.com/ on 04/08/2021
research support from Avanos Medical (previously
Halyard Health), Mallinckrodt Pharmaceuticals,
Mesoblast, and Neuros Medical; and was an
independent medical monitor for this study. No
other disclosures were reported.
Funding/Support: This study was funded by Nevro
Corp.
Role of the Funder/Sponsor: The sponsor
participated in the design of the study in
collaboration with an outside expert advisory
committee as well as the conduct of the study by
supporting patient optimization in collaboration
with the investigators and monitoring data at the
sites. The research site investigators and staff were
responsible for all data collection and management
via entry into a secure database. The sponsor
participated in the analysis and interpretation of
the data along with the authors and an
independent biostatistician. The sponsor also
participated in the preparation, review, and
approval of the manuscript and decision to submit
the manuscript for publication in collaboration with
the authors.
Data Sharing Statement: See Supplement 4.
Additional Contributions: We are grateful to Lisa J.
Stearns, MD (Center for Pain and Supportive Care,
Phoenix, Arizona), and B. Todd Sitzman, MD, MPH
(Advanced Pain Therapy, Hattiesburg, Mississippi),
for their considerate review of each study
participant as independent medical monitors.
Drs Stearns and Sitzman provided invaluable
oversight on each study patient as if they were the
treating physicians, which made the study that
much stronger. In addition, we are indebted to the
staff necessary for all aspects of clinical research,
especially the research coordinators. Finally, we
thank Richard Holcomb, PhD (independent
biostatistician, Minneapolis, Minnesota), for
performing statistical analyses and Brian Levy, MD
(New York University School of Medicine,
New York), for his critical review of the manuscript.
Drs Stearns, Sitzman, Holcomb, and Levy received
consulting fees from the sponsor for their work.
REFERENCES
1. World Health Organization. Global report on
diabetes, 2016. Accessed November 9, 2018.
https://apps.who.int/iris/rest/bitstreams/
909883/retrieve
2. Schmader KE. Epidemiology and impact on
quality of life of postherpetic neuralgia and painful
diabetic neuropathy. Clin J Pain. 2002;18(6):350-354.
doi:10.1097/00002508-200211000-00002
3. Pop-Busui R, Boulton AJ, Feldman EL, et al.
Diabetic neuropathy: a position statement by the
American Diabetes Association. Diabetes Care.
2017;40(1):136-154. doi:10.2337/dc16-2042
4. Bril V, England J, Franklin GM, et al; American
Academy of Neurology; American Association of
Neuromuscular and Electrodiagnostic Medicine;
American Academy of Physical Medicine and
Rehabilitation. Evidence-based guideline:
treatment of painful diabetic neuropathy: report of
the American Academy of Neurology, the American
Association of Neuromuscular and
Electrodiagnostic Medicine, and the American
Academy of Physical Medicine and Rehabilitation.
Neurology. 2011;76(20):1758-1765. doi:10.1212/
WNL.0b013e3182166ebe
5. Gabapentin and risk of severe respiratory
depression. Drug Ther Bull. 2018;56(1):3-4. doi:10.
1136/dtb.2018.1.0571
6. Meisenberg B, Ness J, Rao S, Rhule J, Ley C.
Implementation of solutions to reduce
opioid-induced oversedation and respiratory
depression. Am J Health Syst Pharm. 2017;74(3):
162-169. doi:10.2146/ajhp160208
7. Eipe N, Penning J. Postoperative respiratory
depression with pregabalin: a case series and a
preoperative decision algorithm. Pain Res Manag.
2011;16(5):353-356. doi:10.1155/2011/561604
8. Finnerup NB, Attal N, Haroutounian S, et al.
Pharmacotherapy for neuropathic pain in adults:
a systematic review and meta-analysis. Lancet Neurol.
2015;14(2):162-173. doi:10.1016/S1474-4422(14)
70251-0
9. Yang M, Qian C, Liu Y. Suboptimal treatment of
diabetic peripheral neuropathic pain in the United
States. Pain Med. 2015;16(11):2075-2083. doi:10.
1111/pme.12845
10. Tesfaye S, Watt J, Benbow SJ, Pang KA, Miles J,
MacFarlane IA. Electrical spinal-cord stimulation for
painful diabetic peripheral neuropathy. Lancet.
1996;348(9043):1698-1701. doi:10.1016/S0140-6736
(96)02467-1
11. Kumar K, Toth C, Nath RK. Spinal cord
stimulation for chronic pain in peripheral
neuropathy. Surg Neurol. 1996;46(4):363-369.
doi:10.1016/S0090-3019(96)00191-7
12. de Vos CC, Meier K, Zaalberg PB, et al. Spinal
cord stimulation in patients with painful diabetic
neuropathy: a multicentre randomized clinical trial.
Pain. 2014;155(11):2426-2431. doi:10.1016/
j.pain.2014.08.031
13. van Beek M, Slangen R, Schaper NC, et al.
Sustained treatment effect of spinal cord
stimulation in painful diabetic peripheral
neuropathy: 24-month follow-up of a prospective
two-center randomized controlled trial. Diabetes
Care. 2015;38(9):e132-e134. doi:10.2337/dc15-0740
14. Slangen R, Schaper NC, Faber CG, et al. Spinal
cord stimulation and pain relief in painful diabetic
peripheral neuropathy: a prospective two-center
randomized controlled trial. Diabetes Care. 2014;37
(11):3016-3024. doi:10.2337/dc14-0684
15. van Beek M, Geurts JW, Slangen R, et al.
Severity of neuropathy is associated with long-term
spinal cord stimulation outcome in painful diabetic
peripheral neuropathy: five-year follow-up of a
prospective two-center clinical trial. Diabetes Care.
2018;41(1):32-38. doi:10.2337/dc17-0983
16. Sills S. Treatment of painful polyneuropathies of
diabetic and other origins with 10 kHz SCS: a case
series. Postgrad Med. 2020;132(4):352-357. doi:10.
1080/00325481.2020.1732065
17. Galan V, Scowcroft J, Chang P, et al. 10-kHz
Spinal cord stimulation treatment for painful
diabetic neuropathy: results from post-hoc analysis
of the SENZA-PPN study. Pain Manag. 2020;10(5):
291-300. doi:10.2217/pmt-2020-0033
18. De Carolis G, Paroli M, Tollapi L, et al.
Paresthesia-independence: an assessment of
technical factors related to 10 kHz paresthesia-free
spinal cord stimulation. Pain Physician. 2017;
20(4):331-341.
19. Kapural L, Yu C, Doust MW, et al. Novel 10-kHz
high-frequency therapy (HF10 therapy) is superior
to traditional low-frequency spinal cord stimulation
for the treatment of chronic back and leg pain: the
SENZA-RCT randomized controlled trial.
Anesthesiology. 2015;123(4):851-860. doi:10.1097/
ALN.0000000000000774
20. Kapural L, Yu C, Doust MW, et al. Comparison
of 10-kHz high-frequency and traditional
low-frequency spinal cord stimulation for the
treatment of chronic back and leg pain: 24-month
results from a multicenter, randomized, controlled
pivotal trial. Neurosurgery. 2016;79(5):667-677.
doi:10.1227/NEU.0000000000001418
21. Al-Kaisy A, Van Buyten J-P, Smet I, Palmisani S,
Pang D, Smith T. Sustained effectiveness of 10 kHz
high-frequency spinal cord stimulation for patients
with chronic, low back pain: 24-month results of a
prospective multicenter study. Pain Med. 2014;15
(3):347-354. doi:10.1111/pme.12294
22. Al-Kaisy A, Palmisani S, Smith TE, et al.
Long-term improvements in chronic axial low back
pain patients without previous spinal surgery:
a cohort analysis of 10-kHz high-frequency spinal
cord stimulation over 36 months. Pain Med. 2018;
19(6):1219-1226.
23. Amirdelfan K, Vallejo R, Benyamin R, et al.
High-frequency spinal cord stimulation at 10 kHz
for the treatment of combined neck and arm pain:
results from a prospective multicenter study.
Neurosurgery. 2020;87(2):176-185. doi:10.1093/
neuros/nyz495
24. Al-Kaisy A, Palmisani S, Smith T, Harris S, Pang
D. The use of 10-kilohertz spinal cord stimulation in
a cohort of patients with chronic neuropathic limb
pain refractory to medical management.
Neuromodulation. 2015;18(1):18-23. doi:10.1111/
ner.12237
25. Al-Kaisy A, Van Buyten JP, Carganillo R, et al. 10
kHz SCS therapy for chronic pain, effects on opioid
usage: post hoc analysis of data from two
prospective studies. Sci Rep. 2019;9(1):11441. doi:
10.1038/s41598-019-47792-3
26. Al-Kaisy A, Van Buyten JP, Amirdelfan K, et al.
Opioid-sparing effects of 10 kHz spinal cord
stimulation: a review of clinical evidence. Ann N Y
Acad Sci. 2020;1462(1):53-64. doi:10.1111/nyas.14236
27. El Majdoub F, Neudorfer C, Richter R,
Schieferdecker S, Maarouf M. 10 kHz Cervical SCS
for chronic neck and upper limb pain: 12 months’
results. Ann Clin Transl Neurol. 2019;6(11):2223-2229.
doi:10.1002/acn3.50915
28. DiBenedetto DJ, Wawrzyniak KM, Schatman
ME, Kulich RJ, Finkelman M. 10 kHz Spinal cord
stimulation: a retrospective analysis of real-world
data from a community-based, interdisciplinary
pain facility. J Pain Res. 2018;11:2929-2941. doi:10.
2147/JPR.S188795
29. Mekhail NA, Argoff CE, Taylor RS, et al.
High-frequency spinal cord stimulation at 10 kHz
for the treatment of painful diabetic neuropathy:
design of a multicenter, randomized controlled trial
(SENZA-PDN). Trials. 2020;21(87):1-12. doi:10.
1186/s13063-019-4007-y
30. World Medical Association. World Medical
Association Declaration of Helsinki: ethical
principles for medical research involving human
subjects. JAMA. 2013;310(20):2191-2194. doi:10.
1001/jama.2013.281053
31. McCormack HM, Horne DJ, Sheather S. Clinical
applications of visual analogue scales: a critical
Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy Original Investigation Research
jamaneurology.com (Reprinted) JAMA Neurology Published online April 5, 2021 E11
Downloaded From: https://jamanetwork.com/ on 04/08/2021
review. Psychol Med. 1988;18(4):1007-1019. doi:10.
1017/S0033291700009934
32. Dworkin RH, Turk DC, Revicki DA, et al.
Development and initial validation of an expanded
and revised version of the Short-form McGill Pain
Questionnaire (SF-MPQ-2). Pain. 2009;144(1-2):
35-42. doi:10.1016/j.pain.2009.02.007
33. Bouhassira D, Attal N, Alchaar H, et al.
Comparison of pain syndromes associated with
nervous or somatic lesions and development of a
new neuropathic pain diagnostic questionnaire
(DN4). Pain. 2005;114(1-2):29-36. doi:10.1016/
j.pain.2004.12.010
34. Young MJ, Boulton AJ, MacLeod AF, Williams
DR, Sonksen PH. A multicentre study of the
prevalence of diabetic peripheral neuropathy in the
United Kingdom hospital clinic population.
Diabetologia. 1993;36(2):150-154. doi:10.1007/
BF00400697
35. Ayearst L, Harsanyi Z, Michalko KJ. The Pain
and Sleep Questionnaire three-item index (PSQ-3):
a reliable and valid measure of the impact of pain on
sleep in chronic nonmalignant pain of various
etiologies. Pain Res Manag. 2012;17(4):281-290.
doi:10.1155/2012/635967
36. Herdman M, Gudex C, Lloyd A, et al.
Development and preliminary testing of the new
five-level version of EQ-5D (EQ-5D-5L). Qual Life Res.
2011;20(10):1727-1736. doi:10.1007/
s11136-011-9903-x
37. Booth J, Young MJ. Differences in the
performance of commercially available 10-g
monofilaments. Diabetes Care. 2000;23(7):984-988.
doi:10.2337/diacare.23.7.984
38. Boulton AJ, Armstrong DG, Albert SF, et al;
American Diabetes Association; American
Association of Clinical Endocrinologists.
Comprehensive foot examination and risk
assessment: a report of the task force of the foot
care interest group of the American Diabetes
Association, with endorsement by the American
Association of Clinical Endocrinologists. Diabetes
Care. 2008;31(8):1679-1685. doi:10.2337/dc08-9021
39. England JD, Gronseth GS, Franklin G, et al;
American Academy of Neurology; American
Association of Electrodiagnostic Medicine;
American Academy of Physical Medicine and
Rehabilitation. Distal symmetric polyneuropathy:
a definition for clinical research: report of the
American Academy of Neurology, the American
Association of Electrodiagnostic Medicine, and the
American Academy of Physical Medicine and
Rehabilitation. Neurology. 2005;64(2):199-207.
doi:10.1212/01.WNL.0000149522.32823.EA
40. Amirdelfan K, Gliner BE, Kapural L, et al.
A proposed definition of remission from chronic
pain, based on retrospective evaluation of
24-month outcomes with spinal cord stimulation.
Postgrad Med. 2019;131(4):278-286. doi:10.1080/
00325481.2019.1592401
41. Spallone V, Morganti R, D’Amato C, Greco C,
Cacciotti L, Marfia GA. Validation of DN4 as a
screening tool for neuropathic pain in painful
diabetic polyneuropathy. Diabet Med. 2012;29(5):
578-585. doi:10.1111/j.1464-5491.2011.03500.x
42. McClure NS, Sayah FA, Ohinmaa A, Johnson JA.
Minimally important difference of the EQ-5D-5L
index score in adults with type 2 diabetes. Value
Health. 2018;21(9):1090-1097. doi:10.1016/
j.jval.2018.02.007
43. Freeman R, Durso-Decruz E, Emir B. Efficacy,
safety, and tolerability of pregabalin treatment for
painful diabetic peripheral neuropathy: findings
from seven randomized, controlled trials across a
range of doses. Diabetes Care. 2008;31(7):1448-1454.
doi:10.2337/dc07-2105
44. Hossain SM, Hussain SM, Ekram AR.
Duloxetine in painful diabetic neuropathy:
a systematic review. Clin J Pain. 2016;32(11):1005-
1010. doi:10.1097/AJP.0000000000000343
45. Vinik AI, Shapiro DY, Rauschkolb C, et al.
A randomized withdrawal, placebo-controlled
study evaluating the efficacy and tolerability of
tapentadol extended release in patients with
chronic painful diabetic peripheral neuropathy.
Diabetes Care. 2014;37(8):2302-2309.
doi:10.2337/dc13-2291
46. Al-Kaisy A, Palmisani S, Smith TE, et al. 10 kHz
High-frequency spinal cord stimulation for chronic
axial low back pain in patients with no history of
spinal surgery: a preliminary, prospective, open
label and proof-of-concept study. Neuromodulation.
2017;20(1):63-70. doi:10.1111/ner.12563
47. Eldabe S, Buchser E, Duarte RV. Complications
of spinal cord stimulation and peripheral nerve
stimulation techniques: a review of the literature.
Pain Med. 2016;17(2):325-336.
48. Boulton AJ, Kempler P, Ametov A, Ziegler D.
Whither pathogenetic treatments for diabetic
polyneuropathy? Diabetes Metab Res Rev. 2013;29
(5):327-333. doi:10.1002/dmrr.2397
49. van Beek M, Hermes D, Honig WM, et al.
Long-term spinal cord stimulation alleviates
mechanical hypersensitivity and increases
peripheral cutaneous blood perfusion in
experimental painful diabetic polyneuropathy.
Neuromodulation. 2018;21(5):472-479.
doi:10.1111/ner.12757
50. Castellanos J, Kuo D, Zardouz S, et al.
Evaluation of high frequency spinal cord stimulation
(SCS) on corneal confocal microscopy and
intraepidermal nerve fibers in diabetic peripheral
neuropathy: preliminary findings. Paper presented
at: The 23rd Annual Meeting of the North American
Neuromodulation Society; January 24, 2020;
Las Vegas, NV.
Research Original Investigation Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy
E12 JAMA Neurology Published online April 5, 2021 (Reprinted) jamaneurology.com
Downloaded From: https://jamanetwork.com/ on 04/08/2021
